Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30184759 | 0.82 | KIF11 (0.42) | KIF11TAAR1MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3685988 | 0.78 | TAAR1 (0.45) | KIF11TAAR1MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2701328 | 0.77 | TACR1 (0.51) | KIF11TAAR1MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL29157443 | 0.75 | KIF11 (0.47) | KIF11TAAR1MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL18766166 | 0.72 | KIF11 (0.64) | KIF11TAAR1MAPK1SMN1; SMN2ALDH1A1 | |
| Ethylenediamine SCHEMBL28560172 | 0.71 | MAPK1 (0.77) | KIF11TAAR1MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2698651 | 0.71 | TAAR1 (0.42) | KIF11TAAR1MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3478682 | 0.70 | MAPK1 (0.48) | TAAR1MAPK1SMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL2700899 | 0.70 | MAPK1 (0.48) | TAAR1MAPK1SMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL24011649 | 0.69 | MAPK1 (0.48) | KIF11TAAR1MAPK1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168668-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | disclosed |
| US-20100286202-A1 | New Compounds | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286202-A1 | New Compounds | REN, PCSK9, FURIN | KIF11 1305/4885TAAR1 4096/4885MAPK1 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.